Most importantly, in the current study, positivity for both Fas/FasL on PBMCs emerged as a favorable prognostic marker associated with improved OS rates and an independent factor predicting the low risk for death in patients with metastatic BC. The gene discussed is FASLG; the disease is breast cancer.